KURA Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML.
– Topline data expected early 2025
menin
| 发布于: | Android | 转发：0 | 回复：0 | 喜欢：0 |
KURA Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML.
– Topline data expected early 2025
menin